Experimental drug may benefit some patients with rare form of ALS

When Columbia neurologist and scientist Neil Shneider speaks to his ALS patients who volunteer for experimental therapies, he’s unwaveringly honest. “Patients always ask me, ‘What can I hope to get out of this?”‘ Shneider says. “And I always say, in most clinical trials, our hope is that we can slow the disease or maybe even halt progression.”